BridgeMD
VALSARTAN TREATMENT COMPARED IN RENAL TRANSPLANT RECIPIENTS WITH SIGNS OF POST TRANSPLANT GLOMERULOPATHY
EU CTIS ID: 2024-518723-30-01
What this study is testing
To evaluate whether treatment with an angiotensin II receptor antagonist (ARB) prevents the drop in glomerular filtration in the subgroup of kidney transplant patients with the presence of PECs in the urine.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Written informed consent.
- Stable kidney function understood as a variation in eGFR of less than 15% in the last 3 months.
- Maintenance immunosuppression based on tacrolimus and MMF/MPA.
You likely can't join if
- Active chronic infection by HCV, HBV, HIV.
- Treatment with inhibitors of the renin angiotensin system.
- Double kidney transplant or combined with another organ.
- Maintenance immunosuppression other than tacrolimus and MMF/MPA. eGFR <20 ml/min/1.73m2.
- Physically fertile women who plan to become pregnant, are pregnant and/or breast-feeding, or who do not wish to use an effective method of contraception during their participation in the study.
- Any other medical condition that, in the investigator's judgment, based on the count or review of medical records, could affect the completion of the study, including, but not limited to, visual problems or cognitive impairment. eGFR <20 ml/min/1.73m2.
See the full eligibility criteria
- Written informed consent.
- Stable kidney function understood as a variation in eGFR of less than 15% in the last 3 months.
- Maintenance immunosuppression based on tacrolimus and MMF/MPA.
- Active chronic infection by HCV, HBV, HIV.
- Treatment with inhibitors of the renin angiotensin system.
- Double kidney transplant or combined with another organ.
- Maintenance immunosuppression other than tacrolimus and MMF/MPA. eGFR <20 ml/min/1.73m2.
- Physically fertile women who plan to become pregnant, are pregnant and/or breast-feeding, or who do not wish to use an effective method of contraception during their participation in the study.
- Any other medical condition that, in the investigator's judgment, based on the count or review of medical records, could affect the completion of the study, including, but not limited to, visual problems or cognitive impairment. eGFR <20 ml/min/1.73m2.
- History of allergy or intolerance to renin-angiotensin system inhibitor drugs.
- eGFR <20 ml/min/1.73m2.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.